Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;120(9):1221-9.
doi: 10.1289/ehp.1104477. Epub 2012 May 30.

Pharmaceuticals and personal care products in the environment: what are the big questions?

Alistair B A Boxall  1 , Murray A Rudd, Bryan W Brooks, Daniel J Caldwell, Kyungho Choi, Silke Hickmann, Elizabeth Innes, Kim Ostapyk, Jane P Staveley, Tim Verslycke, Gerald T Ankley, Karen F Beazley, Scott E Belanger, Jason P Berninger, Pedro Carriquiriborde, Anja Coors, Paul C Deleo, Scott D Dyer, Jon F Ericson, François Gagné, John P Giesy, Todd Gouin, Lars Hallstrom, Maja V Karlsson, D G Joakim Larsson, James M Lazorchak, Frank Mastrocco, Alison McLaughlin, Mark E McMaster, Roger D Meyerhoff, Roberta Moore, Joanne L Parrott, Jason R Snape, Richard Murray-Smith, Mark R Servos, Paul K Sibley, Jürg Oliver Straub, Nora D Szabo, Edward Topp, Gerald R Tetreault, Vance L Trudeau, Glen Van Der Kraak
Affiliations
Review

Pharmaceuticals and personal care products in the environment: what are the big questions?

Alistair B A Boxall et al. Environ Health Perspect. 2012 Sep.

Abstract

Background: Over the past 10-15 years, a substantial amount of work has been done by the scientific, regulatory, and business communities to elucidate the effects and risks of pharmaceuticals and personal care products (PPCPs) in the environment.

Objective: This review was undertaken to identify key outstanding issues regarding the effects of PPCPs on human and ecological health in order to ensure that future resources will be focused on the most important areas.

Data sources: To better understand and manage the risks of PPCPs in the environment, we used the "key question" approach to identify the principle issues that need to be addressed. Initially, questions were solicited from academic, government, and business communities around the world. A list of 101 questions was then discussed at an international expert workshop, and a top-20 list was developed. Following the workshop, workshop attendees ranked the 20 questions by importance.

Data synthesis: The top 20 priority questions fell into seven categories: a) prioritization of substances for assessment, b) pathways of exposure, c) bioavailability and uptake, d) effects characterization, e) risk and relative risk, f ) antibiotic resistance, and g) risk management.

Conclusions: A large body of information is now available on PPCPs in the environment. This exercise prioritized the most critical questions to aid in development of future research programs on the topic.

PubMed Disclaimer

Conflict of interest statement

A.B.A.B., J.P.S., T.V., A.C., and P.C.D. have provided consultancy services to the pharmaceutical and personal care product (PPCP) industry. D.J.C., J.P.S., S.E.B., S.D.D., J.F.E., T.G., F.M., R.D.M., R.M.S., and J.O.S. are employed by the PPCP sector. A.B.A.B., B.W.B., K.C., J.P.S., T.V., A.C., P.C.D., F.G., J.P.G., M.V.K., D.G., J.L., J.M.L., J.L.P., M.E.M., M.R.S., P.K.S., E.T., G.R.T. V.L.T., and G.V., D.K. have received funding from industry and/or government for research on PPCP issues. M.A.R., D.J.C., S.E.B., P.C.D., F.M., R.D.M., J.R.S., and R.M.S. have shareholdings in the PPCP sector. S.H., E.I., K.O., G.T.A., K.F.B., J.P.B., P.C., L.H., A.M., R.M., and N.D.S. declare they have no actual or potential competing financial interests.

Figures

Figure 1
Figure 1
Major pathways of PPCP release into the environment. Reproduced from Boxall (2004) with permission from EMBO Reports.
Figure 2
Figure 2
Relationship between results of acute and chronic studies (recommended for use in current regulatory assessment approaches for PPCPs in fish) and reported non­standard end points in fish and invertebrates. Standard acute and chronic data (e.g., fish and invertebrate mortality, reproduction, and growth) were obtained from FASS.se (2011) and several litera­ture sources (Caldwell et al. 2008; Kim et al. 2009; Yamamoto et al. 2007); non­standard end point data were obtained from Corcoran et al. (2010).
See this image and copyright information in PMC

References

    1. Ankley GT, Brooks BW, Huggett DB, Sumpter JP. Repeating history: pharmaceuticals in the environment. Environ Sci Technol. 2007;41:8211–8217. - PubMed
    1. Barraclough D, Kearney T, Croxford A. Bound residues: environmental solution or future problem? Environ Pollut. 2005;133:85–90. - PubMed
    1. Berninger JP, Brooks BW. Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. Toxicol Lett. 2010;193:69–78. - PubMed
    1. Boxall ABA. The environmental side effects of medication. EMBO Rep. 2004;5:1110–1116. - PMC - PubMed
    1. Boxall ABA, Fogg LA, Kay P, Blackwell PA, Pemberton EJ, Croxford A. Prioritisation of veterinary medicines in the UK environment. Toxicol Lett. 2003b;142:207–218. - PubMed

Publication types

MeSH terms

Substances